• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Nevro Corp.

    7/10/24 2:05:48 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email
    SC 13G/A 1 arrowmark-nvro063024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Nevro Corp.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    64157F103

    (CUSIP Number)

     

     

    June 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No. 64157F103
     SCHEDULE 13G/A
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    ArrowMark Colorado Holdings, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    4,289,108
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    4,289,108
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,289,108
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    11.68%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     
     

     

    CUSIP No.  64157F103
     SCHEDULE 13G/A
    Page 3 of 6 Pages

     

    Item 1.(a) Name of Issuer

    Nevro Corp.

    (b) Address of Issuer’s Principal Executive Offices

    1800 Bridge Parkway

    Redwood City, CA 94065

    Item 2.(a) Name of Person Filing

    ArrowMark Colorado Holdings, LLC

    (b) Address of Principal Business Office, or, if none, Residence

    100 Fillmore Street, Suite 325

    Denver, Colorado 80206

    (c) Citizenship

    Please refer to Item 4 on each cover sheet for each filing person

     (d) Title of Class of Securities

    Common Stock, $0.001 par value per share

     (e) CUSIP No.:

    64157F103

     
     

     

    CUSIP No.  64157F103
     SCHEDULE 13G/A
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 64157F103
     SCHEDULE 13G/A
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 4,289,108

    (b) Percent of class: 11.68%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 4,289,108

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 4,289,108

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable

     Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

      

     
     
    CUSIP No. 64157F103
     SCHEDULE 13G/A
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 10, 2024

     

     

      ArrowMark Colorado Holdings, LLC
           
      By:  Richard Grove
        Name:  Richard Grove
        Title:  Chief Compliance Officer

     

     

     

     

     

     

     

    Get the next $NVRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $NVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nevro upgraded by Jefferies with a new price target

      Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

      2/10/25 7:02:54 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously

      2/7/25 8:27:53 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Nevro with a new price target

      Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00

      12/3/24 7:38:11 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Nevro Enters Into Cooperation Agreement With Engaged Capital

      Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

      2/21/24 4:06:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Jon R. Shear as Vice President, Corporate Development

      REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

      4/19/21 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

      REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

      11/30/20 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nevro Corp.

      SC 13G - NEVRO CORP (0001444380) (Subject)

      12/4/24 4:27:18 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nevro Corp.

      SC 13D/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:31:36 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nevro Corp.

      SC 13G/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:18:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

      REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

      1/21/25 4:30:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Financials

    Live finance-specific insights

    See more

    $NVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NVRO
    SEC Filings

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Third-Quarter 2024 Financial Results

      Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

      11/11/24 4:05:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:33 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:35 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:38 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • SEC Form 15-12G filed by Nevro Corp.

      15-12G - NEVRO CORP (0001444380) (Filer)

      4/14/25 8:30:09 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Nevro Corp.

      EFFECT - NEVRO CORP (0001444380) (Filer)

      4/8/25 12:15:06 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

      SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)

      4/4/25 3:49:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care